Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 41

1.

Development of high‑resolution melting analysis for ABCB1 promoter methylation: Clinical consequences in breast and ovarian carcinoma.

Vaclavikova R, Klajic J, Brynychova V, Elsnerova K, Alnaes GIG, Tost J, Kristensen VN, Rob L, Kodet R, Skapa P, Mrhalova M, Soucek P.

Oncol Rep. 2019 Jun 5. doi: 10.3892/or.2019.7186. [Epub ahead of print]

PMID:
31173253
2.

Interferon-regulated suprabasin is essential for stress-induced stem-like cell conversion and therapy resistance of human malignancies.

Hubackova S, Pribyl M, Kyjacova L, Moudra A, Dzijak R, Salovska B, Strnad H, Tambor V, Imrichova T, Svec J, Vodicka P, Vaclavikova R, Rob L, Bartek J, Hodny Z.

Mol Oncol. 2019 Jul;13(7):1467-1489. doi: 10.1002/1878-0261.12480. Epub 2019 Jun 10.

3.

Association of ABC gene profiles with time to progression and resistance in ovarian cancer revealed by bioinformatics analyses.

Seborova K, Vaclavikova R, Soucek P, Elsnerova K, Bartakova A, Cernaj P, Bouda J, Rob L, Hruda M, Dvorak P.

Cancer Med. 2019 Feb;8(2):606-616. doi: 10.1002/cam4.1964. Epub 2019 Jan 22.

4.

Use of Germline Genetic Variability for Prediction of Chemoresistance and Prognosis of Breast Cancer Patients.

Hlavac V, Kovacova M, Elsnerova K, Brynychova V, Kozevnikovova R, Raus K, Kopeckova K, Mestakova S, Vrana D, Gatek J, Ostasov P, Vaclavikova R, Soucek P.

Cancers (Basel). 2018 Dec 12;10(12). pii: E511. doi: 10.3390/cancers10120511.

5.

ABC Transporters and Their Role in the Neoadjuvant Treatment of Esophageal Cancer.

Vrana D, Hlavac V, Brynychova V, Vaclavikova R, Neoral C, Vrba J, Aujesky R, Matzenauer M, Melichar B, Soucek P.

Int J Mol Sci. 2018 Mar 15;19(3). pii: E868. doi: 10.3390/ijms19030868. Review.

6.

Gene Expression Profiling Reveals Novel Candidate Markers of Ovarian Carcinoma Intraperitoneal Metastasis.

Elsnerova K, Bartakova A, Tihlarik J, Bouda J, Rob L, Skapa P, Hruda M, Gut I, Mohelnikova-Duchonova B, Soucek P, Vaclavikova R.

J Cancer. 2017 Oct 9;8(17):3598-3606. doi: 10.7150/jca.20766. eCollection 2017.

7.

The role of membrane transporters in ovarian cancer chemoresistance and prognosis.

Cerovska E, Elsnerova K, Vaclavikova R, Soucek P.

Expert Opin Drug Metab Toxicol. 2017 Jul;13(7):741-753. doi: 10.1080/17425255.2017.1332179. Epub 2017 May 29. Review.

PMID:
28511565
8.

Expression of oxysterol pathway genes in oestrogen-positive breast carcinomas.

Kloudova A, Brynychova V, Vaclavikova R, Vrana D, Gatek J, Mrhalova M, Kodet R, Soucek P.

Clin Endocrinol (Oxf). 2017 Jun;86(6):852-861. doi: 10.1111/cen.13337. Epub 2017 Apr 24.

PMID:
28342201
9.

[Clinical and Functional Importance of Selected CASP8 and CASP9 Polymorphisms in Breast Carcinoma].

Brynychová V, Václavíková R, Kubáčková K, Mrhalová M, Kodet R, Rauš K, Vrána D, Gatěk J, Bendová M, Souček P.

Klin Onkol. Winter 2016;29(6):445-453. Czech.

PMID:
27951722
10.

Genetic and functional analyses do not explain the association of high PRC1 expression with poor survival of breast carcinoma patients.

Brynychova V, Ehrlichova M, Hlavac V, Nemcova-Furstova V, Pecha V, Leva J, Trnkova M, Mrhalova M, Kodet R, Vrana D, Kovar J, Vaclavikova R, Gut I, Soucek P.

Biomed Pharmacother. 2016 Oct;83:857-864. doi: 10.1016/j.biopha.2016.07.047. Epub 2016 Aug 6.

PMID:
27505863
11.

Characterization of acquired paclitaxel resistance of breast cancer cells and involvement of ABC transporters.

Němcová-Fürstová V, Kopperová D, Balušíková K, Ehrlichová M, Brynychová V, Václavíková R, Daniel P, Souček P, Kovář J.

Toxicol Appl Pharmacol. 2016 Nov 1;310:215-228. doi: 10.1016/j.taap.2016.09.020. Epub 2016 Sep 21.

PMID:
27664577
12.

Transcript expression and genetic variability analysis of caspases in breast carcinomas suggests CASP9 as the most interesting target.

Brynychova V, Hlavac V, Ehrlichova M, Vaclavikova R, Nemcova-Furstova V, Pecha V, Trnkova M, Mrhalova M, Kodet R, Vrana D, Gatek J, Bendova M, Vernerova Z, Kovar J, Soucek P.

Clin Chem Lab Med. 2017 Jan 1;55(1):111-122. doi: 10.1515/cclm-2016-0271.

PMID:
27327132
13.

Gene expression of membrane transporters: Importance for prognosis and progression of ovarian carcinoma.

Elsnerova K, Mohelnikova-Duchonova B, Cerovska E, Ehrlichova M, Gut I, Rob L, Skapa P, Hruda M, Bartakova A, Bouda J, Vodicka P, Soucek P, Vaclavikova R.

Oncol Rep. 2016 Apr;35(4):2159-70. doi: 10.3892/or.2016.4599. Epub 2016 Jan 28.

PMID:
26820484
14.

Whole exome sequencing analysis of ABCC8 and ABCD2 genes associating with clinical course of breast carcinoma.

Soucek P, Hlavac V, Elsnerova K, Vaclavikova R, Kozevnikovova R, Raus K.

Physiol Res. 2015;64 Suppl 4:S549-57.

15.

Microsomal epoxide hydrolase 1 (EPHX1): Gene, structure, function, and role in human disease.

Václavíková R, Hughes DJ, Souček P.

Gene. 2015 Oct 15;571(1):1-8. doi: 10.1016/j.gene.2015.07.071. Epub 2015 Jul 26. Review.

16.

The role of cytochromes p450 and aldo-keto reductases in prognosis of breast carcinoma patients.

Hlaváč V, Brynychová V, Václavíková R, Ehrlichová M, Vrána D, Pecha V, Trnková M, Kodet R, Mrhalová M, Kubáčková K, Gatěk J, Vážan P, Souček P.

Medicine (Baltimore). 2014 Dec;93(28):e255. doi: 10.1097/MD.0000000000000255.

17.

Can the assessment of ABCB1 gene expression predict its function in vitro?

Kosztyu P, Dolezel P, Vaclavikova R, Mlejnek P.

Eur J Haematol. 2015 Aug;95(2):150-9. doi: 10.1111/ejh.12470. Epub 2015 Jan 22.

PMID:
25323158
18.

Non-coding polymorphisms in nucleotide binding domain 1 in ABCC1 gene associate with transcript level and survival of patients with breast cancer.

Kunická T, Václavíková R, Hlaváč V, Vrána D, Pecha V, Rauš K, Trnková M, Kubáčková K, Ambruš M, Vodičková L, Vodička P, Souček P.

PLoS One. 2014 Jul 31;9(7):e101740. doi: 10.1371/journal.pone.0101740. eCollection 2014.

19.

The expression profile of ATP-binding cassette transporter genes in breast carcinoma.

Hlaváč V, Brynychová V, Václavíková R, Ehrlichová M, Vrána D, Pecha V, Koževnikovová R, Trnková M, Gatěk J, Kopperová D, Gut I, Souček P.

Pharmacogenomics. 2013 Apr;14(5):515-29. doi: 10.2217/pgs.13.26.

PMID:
23556449
20.

The association of taxane resistance genes with the clinical course of ovarian carcinoma.

Ehrlichova M, Mohelnikova-Duchonova B, Hrdy J, Brynychova V, Mrhalova M, Kodet R, Rob L, Pluta M, Gut I, Soucek P, Vaclavikova R.

Genomics. 2013 Aug;102(2):96-101. doi: 10.1016/j.ygeno.2013.03.005. Epub 2013 Mar 28.

21.

Importance of transcript levels of caspase-2 isoforms S and L for breast carcinoma progression.

Brynychová V, Hlaváč V, Ehrlichová M, Václavíková R, Pecha V, Trnková M, Wald M, Mrhalová M, Kubáčková K, Pikus T, Kodet R, Kovář J, Souček P.

Future Oncol. 2013 Mar;9(3):427-38. doi: 10.2217/fon.12.200.

PMID:
23469978
22.

Detection of frequent ABCB1 polymorphisms by high-resolution melting curve analysis and their effect on breast carcinoma prognosis.

Vaclavikova R, Ehrlichova M, Hlavata I, Pecha V, Kozevnikovova R, Trnkova M, Adamek J, Edvardsen H, Kristensen VN, Gut I, Soucek P.

Clin Chem Lab Med. 2012 Nov;50(11):1999-2007. doi: 10.1515/cclm-2012-0103.

PMID:
23093106
23.

Transport, metabolism, cytotoxicity and effects of novel taxanes on the cell cycle in MDA-MB-435 and NCI/ADR-RES cells.

Ehrlichová M, Ojima I, Chen J, Václavíková R, Němcová-Fürstová V, Vobořilová J, Simek P, Horský S, Souček P, Kovář J, Brabec M, Gut I.

Naunyn Schmiedebergs Arch Pharmacol. 2012 Oct;385(10):1035-48. doi: 10.1007/s00210-012-0785-4. Epub 2012 Aug 2.

PMID:
22855252
24.

The role of ABC transporters in progression and clinical outcome of colorectal cancer.

Hlavata I, Mohelnikova-Duchonova B, Vaclavikova R, Liska V, Pitule P, Novak P, Bruha J, Vycital O, Holubec L, Treska V, Vodicka P, Soucek P.

Mutagenesis. 2012 Mar;27(2):187-96. doi: 10.1093/mutage/ger075.

PMID:
22294766
25.

Beta-3 agonist-induced lipolysis and nitric oxide production: relationship to PPARgamma agonist/antagonist and AMP kinase modulation.

Hodis J, Vaclavíková R, Farghali H.

Gen Physiol Biophys. 2011 Mar;30(1):90-9. doi: 10.4149/gpb_2011_01_90.

PMID:
21460417
26.

Second-generation taxanes effectively suppress subcutaneous rat lymphoma: role of disposition, transport, metabolism, in vitro potency and expression of angiogenesis genes.

Otová B, Ojima I, Václavíková R, Hrdý J, Ehrlichová M, Souček P, Vobořilová J, Němcová V, Zanardi I, Horský S, Kovář J, Gut I.

Invest New Drugs. 2012 Jun;30(3):991-1002. doi: 10.1007/s10637-011-9654-0. Epub 2011 Mar 30.

PMID:
21448670
27.

Association of superoxide dismutases and NAD(P)H quinone oxidoreductases with prognosis of patients with breast carcinomas.

Hubackova M, Vaclavikova R, Ehrlichova M, Mrhalova M, Kodet R, Kubackova K, Vrána D, Gut I, Soucek P.

Int J Cancer. 2012 Jan 15;130(2):338-48. doi: 10.1002/ijc.26006. Epub 2011 Apr 20.

28.

DNA damage, DNA repair rates and mRNA expression levels of cell cycle genes (TP53, p21(CDKN1A), BCL2 and BAX) with respect to occupational exposure to styrene.

Hanova M, Vodickova L, Vaclavikova R, Smerhovsky Z, Stetina R, Hlavac P, Naccarati A, Slyskova J, Polakova V, Soucek P, Kumar R, Hemminki K, Vodicka P.

Carcinogenesis. 2011 Jan;32(1):74-9. doi: 10.1093/carcin/bgq213. Epub 2010 Oct 21.

PMID:
20966084
29.

Modulation of DNA repair capacity and mRNA expression levels of XRCC1, hOGG1 and XPC genes in styrene-exposed workers.

Hanova M, Stetina R, Vodickova L, Vaclavikova R, Hlavac P, Smerhovsky Z, Naccarati A, Polakova V, Soucek P, Kuricova M, Manini P, Kumar R, Hemminki K, Vodicka P.

Toxicol Appl Pharmacol. 2010 Nov 1;248(3):194-200. doi: 10.1016/j.taap.2010.07.027. Epub 2010 Aug 6.

PMID:
20692273
30.

NAD(P)H:quinone oxidoreductase 1 Pro187Ser polymorphism and expression do not cosegregate with clinico-pathological characteristics of human mammary tumors.

Hubackova M, Vaclavikova R, Mrhalova M, Kubackova K, Kodet R, Gut I, Soucek P.

Pharmacogenet Genomics. 2009 Jul;19(7):505-12. doi: 10.1097/FPC.0b013e32832cf9cf.

PMID:
19494791
31.

Single nucleotide polymorphisms in the multidrug resistance gene 1 (ABCB1): effects on its expression and clinicopathological characteristics in breast cancer patients.

Vaclavikova R, Nordgard SH, Alnaes GI, Hubackova M, Kubala E, Kodet R, Mrhalova M, Novotny J, Gut I, Kristensen VN, Soucek P.

Pharmacogenet Genomics. 2008 Mar;18(3):263-73. doi: 10.1097/FPC.0b013e3282f60a91.

PMID:
18300948
32.

RNA expression of cytochrome P450 in breast cancer patients.

Vaclavikova R, Hubackova M, Stribrna-Sarmanova J, Kodet R, Mrhalova M, Novotny J, Gut I, Soucek P.

Anticancer Res. 2007 Nov-Dec;27(6C):4443-50.

33.

The effect of flavonoid derivatives on doxorubicin transport and metabolism.

Václavíková R, Kondrová E, Ehrlichová M, Boumendjel A, Kovár J, Stopka P, Soucek P, Gut I.

Bioorg Med Chem. 2008 Feb 15;16(4):2034-42. Epub 2007 Nov 4.

PMID:
18024139
34.

The anticancer drug ellipticine is a potent inducer of rat cytochromes P450 1A1 and 1A2, thereby modulating its own metabolism.

Aimová D, Svobodová L, Kotrbová V, Mrázová B, Hodek P, Hudecek J, Václavíková R, Frei E, Stiborová M.

Drug Metab Dispos. 2007 Oct;35(10):1926-34. Epub 2007 Jul 26.

PMID:
17656468
35.

Effects of paclitaxel, docetaxel and their combinations on subcutaneous lymphomas in inbred Sprague-Dawley/Cub rats.

Otová B, Václavíková R, Danielová V, Holubová J, Ehrlichová M, Horský S, Soucek P, Simek P, Gut I.

Eur J Pharm Sci. 2006 Dec;29(5):442-50. Epub 2006 Aug 23.

PMID:
17000091
36.

Metabolism of new-generation taxanes in human, pig, minipig and rat liver microsomes.

Gut I, Ojima I, Vaclavikova R, Simek P, Horsky S, Linhart I, Soucek P, Kondrova E, Kuznetsova LV, Chen J.

Xenobiotica. 2006 Sep;36(9):772-92.

PMID:
16971343
37.

Modulation of paclitaxel transport by flavonoid derivatives in human breast cancer cells. Is there a correlation between binding affinity to NBD of P-gp and modulation of transport?

Václavíková R, Boumendjel A, Ehrlichová M, Kovár J, Gut I.

Bioorg Med Chem. 2006 Jul 1;14(13):4519-25. Epub 2006 Mar 3.

PMID:
16516478
38.

Cell death induced by taxanes in breast cancer cells: cytochrome C is released in resistant but not in sensitive cells.

Ehrlichová M, Koc M, Truksa J, Naldová Z, Václavíková R, Kovárr J.

Anticancer Res. 2005 Nov-Dec;25(6B):4215-24.

39.

Transport and cytotoxicity of paclitaxel, docetaxel, and novel taxanes in human breast cancer cells.

Ehrlichova M, Vaclavikova R, Ojima I, Pepe A, Kuznetsova LV, Chen J, Truksa J, Kovar J, Gut I.

Naunyn Schmiedebergs Arch Pharmacol. 2005 Jul;372(1):95-105. Epub 2005 Jul 30.

PMID:
16059735
40.

Different in vitro metabolism of paclitaxel and docetaxel in humans, rats, pigs, and minipigs.

Vaclavikova R, Soucek P, Svobodova L, Anzenbacher P, Simek P, Guengerich FP, Gut I.

Drug Metab Dispos. 2004 Jun;32(6):666-74.

PMID:
15155559
41.

Paclitaxel metabolism in rat and human liver microsomes is inhibited by phenolic antioxidants.

Václavíková R, Horský S, Simek P, Gut I.

Naunyn Schmiedebergs Arch Pharmacol. 2003 Sep;368(3):200-9. Epub 2003 Aug 14.

PMID:
12920504

Supplemental Content

Loading ...
Support Center